These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35832452)

  • 21. Malignant Mesothelioma Versus Metastatic Carcinoma of the Pleura: A CT Challenge.
    Bakhshayesh Karam M; Karimi S; Mosadegh L; Chaibakhsh S
    Iran J Radiol; 2016 Jan; 13(1):e10949. PubMed ID: 27110327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
    Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in-vitro.
    Jagirdar RM; Papazoglou ED; Pitaraki E; Kouliou OA; Rouka E; Giannakou L; Giannopoulos S; Sinis SI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Clin Exp Pharmacol Physiol; 2021 Apr; 48(4):543-552. PubMed ID: 33336399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
    Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
    Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling.
    Roshini A; Goparaju C; Kundu S; Nandhu MS; Longo SL; Longo JA; Chou J; Middleton FA; Pass HI; Viapiano MS
    Front Oncol; 2022; 12():1014749. PubMed ID: 36303838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.
    Keshava S; Sahoo S; Tucker TA; Idell S; Rao LV; Pendurthi UR
    Cancer Res; 2013 Jul; 73(13):3963-73. PubMed ID: 23539451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.
    Tsuji S; Tsuura Y; Morohoshi T; Shinohara T; Oshita F; Yamada K; Kameda Y; Ohtsu T; Nakamura Y; Miyagi Y
    Br J Cancer; 2010 Aug; 103(4):517-23. PubMed ID: 20628387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
    Yoneda K; Tanaka F; Kondo N; Orui H; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Nakano T; Hasegawa S
    Ann Surg Oncol; 2012 Dec; 19(13):4229-37. PubMed ID: 22825770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.
    Jamal S; Cheriyan VT; Muthu M; Munie S; Levi E; Ashour AE; Pass HI; Wali A; Singh M; Rishi AK
    PLoS One; 2014; 9(3):e89146. PubMed ID: 24598827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
    Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
    J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.
    Takeuchi S; Fukuda K; Yamada T; Arai S; Takagi S; Ishii G; Ochiai A; Iwakiri S; Itoi K; Uehara H; Nishihara H; Fujita N; Yano S
    Cancer Sci; 2017 Apr; 108(4):696-703. PubMed ID: 28182302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.